Journal
TRANSLATIONAL RESEARCH
Volume 225, Issue -, Pages 70-81Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.trsl.2020.04.006
Keywords
-
Categories
Funding
- NIAMS NIH HHS [R01 AR069572] Funding Source: Medline
Ask authors/readers for more resources
Antiphospholipid syndrome is one of the more common acquired causes of hypercoagulability. Its major presentations are thrombotic (arterial, venous, or microvascular) and pregnancy morbidity (miscarriages, late intrauterine fetal demise, and severe preeclampsia). Classification criteria include 3 different antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, and anti-beta 2 glycoprotein I. Management includes both preventive strategies (low-dose aspirin, hydroxychloroquine) and long-term anticoagulation after thrombosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available